Chadha Krishdeep Singh, Schiff Michael, Sitrin Michael D, Wilding Gregory E, Nava Hector
Division of Gastroenterology, Hepatology and Nutrition, State University of New York at Buffalo, ECMC, 462 Grider Street, Buffalo, NY 14215, USA.
J Gastrointest Cancer. 2010 Sep;41(3):173-8. doi: 10.1007/s12029-010-9133-4.
Esophageal stents have been used as first-line treatment for palliation of malignant dysphagia, but this is associated with significant complications. The present study evaluated clinical outcomes and survival in patients with malignant dysphagia with esophageal stent placement who did not respond to prior chemoradiation or endoscopic modalities.
Patients with esophageal cancer, who had esophageal stents, were retrospectively reviewed from the electronic medical records. The patient demographics, type of stent placed, dysphagia scores, stent-related complications, and survival were recorded.
Thirty-five patients with esophageal cancer received a total of 41 stents. There were 25 males and 10 females with mean age of 69.8 years. Twenty-two patients had esophageal adenocarcinoma, ten patients had squamous cell carcinoma, and three had poorly differentiated tumor. Esophageal malignancy was early stage (I, II) in 10 patients and advanced (III, IV) in 24 patients. Three patients had upper esophageal involvement, eight patients had mid-esophageal involvement; distal esophageal malignancy was present in 24 patients with 10 patients having gastroesophageal junction involvement. Six patients presented with tracheoesophageal fistula. Nine patients had prior esophagectomy. Thirty-three patients had chemoradiation, and 32 patients had other endoscopic therapies previously. Twelve of the 35 (33%) patients developed stent-related complications; nine patients had dysphagia due to various causes; one patient each developed aspiration, intractable hiccups, and intractable vomiting after stent placement, respectively. Nine patients underwent a repeat esophagogastroduodenoscopy. Development of stent-related complications was not significantly associated with poor survival.
The clinical outcomes for patients with esophageal stent placement for malignant dysphagia after chemoradiation and other endoscopic treatments is not worse than that reported in patients where esophageal stent placement was used as first-line treatment.
食管支架已被用作缓解恶性吞咽困难的一线治疗方法,但这会引发严重并发症。本研究评估了对先前放化疗或内镜治疗无反应的恶性吞咽困难患者放置食管支架后的临床结局和生存率。
从电子病历中回顾性分析放置食管支架的食管癌患者。记录患者的人口统计学资料、所放置支架的类型、吞咽困难评分、支架相关并发症及生存率。
35例食管癌患者共置入41枚支架。其中男性25例,女性10例,平均年龄69.8岁。22例患者为食管腺癌,10例为鳞状细胞癌,3例为低分化肿瘤。10例患者的食管恶性肿瘤处于早期(I、II期),24例处于晚期(III、IV期)。3例患者食管上段受累,8例患者食管中段受累;24例患者食管下段有恶性肿瘤,其中10例患者胃食管交界处受累。6例患者出现气管食管瘘。9例患者曾接受食管切除术。33例患者接受过放化疗,32例患者曾接受过其他内镜治疗。35例患者中有12例(33%)发生支架相关并发症;9例患者因各种原因出现吞咽困难;1例患者在支架置入后分别出现误吸、顽固性呃逆和顽固性呕吐。9例患者接受了重复食管胃十二指肠镜检查。支架相关并发症的发生与生存率不佳无显著相关性。
放化疗及其他内镜治疗后因恶性吞咽困难而放置食管支架的患者,其临床结局并不比将食管支架置入作为一线治疗的患者所报告的结局差。